Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cannabinoids in multiple sclerosis -- therapeutically reasonable?].

C Trebst1, M Stangel

  • 1Neurologische Klinik mit Klinischer Neurophysiologie, Medizinische Hochschule Hannover. trebst.corinna@mh-hannover.de

Fortschritte Der Neurologie-Psychiatrie
|July 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.

Journal of neurology·2024
Same author

A rare case of neuro- and otosyphilis in secondary syphilis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

S1 guidelines "lumbar puncture and cerebrospinal fluid analysis" (abridged and translated version).

Neurological research and practice·2020
Same author

Standardized nutritional supply versus individual nutritional assessment: Impact on weight changes, complications and functional outcome from neurological early rehabilitation.

Clinical nutrition (Edinburgh, Scotland)·2019
Same author

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Der Nervenarzt·2018
Same author

[Neurological complications of infections with (novel) enteroviruses].

Der Nervenarzt·2018
Same journal

[Rare hereditary and acquired diseases with parkinson's syndrome].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Digital transformation in multiple sclerosis: Advances in diagnostics, monitoring and patient-centred care].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Dementia with Lewy bodies].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Impact of the PEPP reimbursement system and other developments on inpatient care of general psychiatry patients 2005 to 2022: a retrospective analysis].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[The pathology of the brain eating amoeba Naegleria fowleri].

Fortschritte der Neurologie-Psychiatrie·2026
Same journal

[Chronic vestibular syndromes: Correct diagnosis and treatment].

Fortschritte der Neurologie-Psychiatrie·2026
See all related articles

Cannabis sativa extracts show promise for multiple sclerosis (MS) symptom relief, including spasticity and pain. While research suggests therapeutic potential, current clinical trial data do not support general use in MS patients.

Area of Science:

  • Neurology
  • Pharmacology

Context:

  • Cannabis sativa extracts have historical uses.
  • Anecdotal evidence suggests benefits for multiple sclerosis (MS) symptoms like spasticity and pain.
  • Growing interest in cannabinoids for MS treatment.

Purpose:

  • To review current clinical and experimental research on the therapeutic potential of cannabinoids for MS.
  • To evaluate the efficacy of cannabinoids in managing MS-related symptoms.

Summary:

  • A recent large, multicenter, double-blind, placebo-controlled study investigated cannabinoids for MS spasticity and symptoms.
  • Evidence from this trial, prior uncontrolled observations, and preclinical research supports the therapeutic use of cannabinoids in MS.
  • Emerging data indicate cannabinoids possess immunomodulatory and neuroprotective properties.

Related Experiment Videos

Impact:

  • Cannabinoids show reasonable evidence for treating MS symptoms.
  • Clinical trial results currently preclude a general recommendation for cannabinoid use in MS.
  • Further research is needed to establish definitive treatment guidelines.